Qualigen Therapeutics, Inc. (QLGN) Research

Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.

Market snapshot

Symbol
QLGN
Price
$3.21
Day change
+5.59%
Market cap
$7.5M
P/E ratio
-0.55x
52-week range
1.61-8.81
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Can-Fite BioPharma Ltd. (CANF)
  • Clearmind Medicine Inc. (CMND)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • Ensysce Biosciences, Inc. (ENSC)
  • KALA BIO, Inc. (KALA)
  • Kazia Therapeutics Limited (KZIA)
  • Oragenics, Inc. (OGEN)
  • Soligenix, Inc. (SNGX)

Recent insider activity

  • Bensler Graydon — trade (0 shares) on 2024-11-07
  • Braeden Lichti — trade (0 shares) on 2024-10-08
  • LIM ROBERT BRADLEY — trade (0 shares) on 2024-07-12
  • BECHER CAMPBELL — trade (0 shares) on 2024-07-12
  • PRICE CODY — trade (0 shares) on 2024-07-12

Open Qualigen Therapeutics, Inc. (QLGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.